Ceska gynekologie · 2010
[Hormonal treatment effectivity in hyperandrogenic syndrome].
Аннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Visnovský J, Biringer K, Svecová I, Biringerová Z
Аннотация
OBJECTIVE: To evaluate effectiveness of hormonal treatment of hyperandrogenic syndrome (HAS).
DESIGN: Prospective randomized study.
SETTING: Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.
METHODS: We assessed effect of one-year-long hormonal treatment on menstrual cycles (MC), clinical signs of HAS, and ultrasound finding (USG) in 90 patients with HAS. Patients were divided into three groups with 30 females: A--35 microg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day; B--30 microg EE with 2.0 mg dienogest/day; C--30 microg EE with 3.0 mg drospirenone/day.
RESULTS: It was achieved a positive effect on MC regularity in every group during the first six months of treatment (p < 0.001). Signs of hirsutism, virilization, and USG finding were significantly better in group A.
CONCLUSION: The most effective hormonal treatment in our study was the combination of 35 microg EE with 2.0 mg cyproterone acetate/day.
DESIGN: Prospective randomized study.
SETTING: Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.
METHODS: We assessed effect of one-year-long hormonal treatment on menstrual cycles (MC), clinical signs of HAS, and ultrasound finding (USG) in 90 patients with HAS. Patients were divided into three groups with 30 females: A--35 microg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day; B--30 microg EE with 2.0 mg dienogest/day; C--30 microg EE with 3.0 mg drospirenone/day.
RESULTS: It was achieved a positive effect on MC regularity in every group during the first six months of treatment (p < 0.001). Signs of hirsutism, virilization, and USG finding were significantly better in group A.
CONCLUSION: The most effective hormonal treatment in our study was the combination of 35 microg EE with 2.0 mg cyproterone acetate/day.